Korea Biomedical Review on LinkedIn: [ASCO 2024] Osimertinib emerges as an ‘one-fits-all’ treatment for all… (2024)

Shaperon, a Korean biotech firm listed on Kosdaq, signed a collaborative research agreement with Korea University's Research Institute for Medical Service Innovation to develop a treatment for respiratory failure that occurs during cardiopulmonary bypass surgery using NuSepin, an inflammatory complex inhibitor.https://lnkd.in/gj38VCiz

3

Neurology, orthopedics, orthopedic surgery, respiratory medicine, cancer, endocrinology, and pediatrics were the most prominent clinical areas Korean hospitals excelled in the Asia-Pacific region.In pediatrics in particular, 28 Korean hospitals are among the top 100 in this part of the world, according to the Newsweek magazine.#hospitalrankings #pediatrics #neurology #orthopedics #cancer Asan Medical Center (AMC) Severance Hospital Seoul National University Hospital Seoul St. Mary's Hospital, Office of International Collaboration and Affairshttps://lnkd.in/g4_y_-tE

2

A recent study conducted at Severance Hospital, Yonsei University, confirmed that usingticagrelormonotherapy proves to be both effective and safe for patients who have undergone drug-eluting stent (DES) implantation as part of their treatment for acutecoronary syndrome (ACS) and have been on short-term dual antiplatelet therapy (DAPT) for less than three months.#TicagrelorMonotherapy #SeverenceHospital #YonseiUniversity #AcuteCoronarySyndrome #CoronaryArteryDiseasehttps://lnkd.in/gXHCdDi6

Samsung Biologics CEO John Rim predicts the antibody drug market will grow over 10 percent annually, driven by expanding therapeutic areas and new biopharma innovations. At a press conference, Rim highlighted the company’s advancements in #ADC production and its strategic partnerships with top global pharmaceutical firms. He emphasized Samsung Biologics’ role in addressing client needs through #CDO and #CMO services, noting significant growth opportunities in the biopharma sector. Read the full article here:https://lnkd.in/gf76pzYn

18

[Breaking News] Senior doctors at four hospitals affiliated with Seoul National University (SNU) will suspend all medical services, except emergency and critical care, starting June 17. This decision came as a protest against the planned government penalties on resigned junior physicians. Affected hospitals include Seoul National University Hospital, 분당서울대학교병원 (SNUH Bundang Hospital) ®, Seoul Metropolitan Government SNU Boramae Medical Center, and SNU Hospital Healthcare System Gangnam Center.Patient groups have condemned the strike, calling it "selfish behavior."https://lnkd.in/gsj7rB78

GSK foresees supply shortage of asthma inhaler Ventolin Nebule 2.5mg in Korea#asthmainhaler #asthma #Ventolin https://lnkd.in/gvYAdTS6

1

분당서울대학교병원 (SNUH Bundang Hospital) ® said it hosted a Global Nursing Leadership Academy for nursing managers from the First Affiliated Hospital of Wenzhou Medical University (WMU) in Wenzhou, Zhejiang, China.This initiative, part of SNUBH's ongoing commitment to international nursing exchange and capacity building, offered specialized courses in various nursing specialties, including geriatric, surgical, and critical care nursing.#HealthcarePartnerships #KoreaChinaExchange #NursingCourseshttps://lnkd.in/gfHXvbSy

[BIO USA 2024] FDA rejection of HLB's rivoceranib approval linked to impact of Biosecure Act?BIO International Convention #BIO24 #BiosecureAct KoreaBIO BIOTECHNOLOGY INDUSTRY ORGANIZATION https://lnkd.in/g6XYS6hh

9

[#ASCO24] Janssen Inc.'s new subcutaneous formulation of #Rybrevant matches the intravenous version's efficacy while reducing adverse reactions. This advancement enhances the U.S. approval prospects for Yuhan Corporation's Leclaza. The MARIPOSA and PALOMA-3 studies reveal the significant efficacy of the Rybrevant and Leclaza combination in high-risk EGFR-mutant #NSCLC patients. These findings could redefine first-line treatment options and establish a new standard of care. #amivantamab #lazertinib #lungcancer #EGFR American Society of Clinical Oncology (ASCO) Enriqueta Felip https://lnkd.in/g6ccpv-9

5

NeoImmuneTech, a Korean clinical-stage T cell-focused biotech company,said on Tuesday that NT-I7 (efineptakin alfa) has been granted organ drug designation (#ODD) for acute radiation syndrome (ARS) by the European Medicines Agency (EMA).#acuteradiationsyndrome #ARS https://lnkd.in/gZhStnXG

2